论文部分内容阅读
以乳糖化人血清白蛋白作为载体，与抗病毒药物单磷酸阿糖腺苷交联成导向抗病毒治疗药物（以下简称交联物），研究其对肝脏的导向性能。同位素标记示踪实验显示，交联物在肝脏内含量明显高于其它脏器（Ｐ＜０．００１）；用胶体金银染色法显示，受体定位于肝细胞血窦面及其侧面；交联物内化实验研究显示，其内化过程及动力学变化符合导向治疗要求。本研究为抗肝炎病毒导向治疗的临床应用提供实验依据。
Using lactosylated human serum albumin as a carrier, it was cross-linked with the antiviral drug vitexin adenosine monophosphate into an anti-viral therapeutic drug (hereinafter referred to as cross-linker) to study its liver targeting performance. Isotope-labeled tracer experiments showed that the content of the cross-linked substance in the liver was significantly higher than that of other organs (P <0.001). Colloidal gold-silver staining showed that the receptor was located on the side of the sinusoid and its side of liver cells. The experimental study of compound internalization shows that the internalization process and the change of kinetics are in line with the guideline treatment requirements. This study provides an experimental basis for the clinical application of anti-hepatitis virus-directed therapy.